Dova Pharmaceuticals Inc (DOVA):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Dova Pharmaceuticals Inc (DOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8176)・商品コード:DATA904C8176
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:32
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Dova Pharmaceuticals Inc (Dova), formerly PBM AKX Holdings LLC, is a clinical-stage pharmaceutical company that acquires, develops and commercializes therapies for the treatment of orphan diseases. The company’s lead candidate, Avatrombopag (DOPTELET), a novel, oral thrombopoietin receptor agonist, is approved byFDA for the treatment of thrombocytopenia in patients suffering from chronic liver disease. Its product candidate stimulates platelet production and limits platelet transfusion-associated risks including infections, immune reactions and refractories. The company develops therapies for the acute treatment and chronic treatment of thrombocytopenia and cancer. Dova is headquartered in Durham, North Carolina, the US.

Dova Pharmaceuticals Inc (DOVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Dova Pharma Raises USD10 Million in Venture Financing 10
Partnerships 11
Dova Pharma and Valeant Pharma Enter into Co-Promotion Agreement 11
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 12
Equity Offering 13
Dova Pharma Plans to Raise up to USD300 Million in Public Offering of Securities 13
Dova Pharma Prices Public Offering of Shares for USD80 Million 14
Dova Pharma Raises USD75 Million in IPO 15
Dova Pharma Raises USD0.2 Million in Private Placement of Units 16
Acquisition 17
Perceptive Advisor Acquires 6.8% Stake in Dova Pharma 17
Dova Pharma Acquires AkaRx from Eisai 18
Dova Pharmaceuticals Inc – Key Competitors 19
Dova Pharmaceuticals Inc – Key Employees 20
Dova Pharmaceuticals Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 09, 2018: Dova Pharmaceuticals reports second quarter 2018 operating and financial results 22
May 09, 2018: Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results 24
Feb 15, 2018: Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results 26
Nov 09, 2017: Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results 27
Aug 10, 2017: Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results 28
Corporate Communications 29
Jun 25, 2018: Dova Pharmaceuticals Names Nancy J. Wysenski As Board Director 29
Jan 30, 2018: Dova Pharmaceuticals Names Mark W. Hahn As Chief Financial Officer 30
Jan 06, 2017: Dova Pharmaceuticals Announces Hiring of CEO and Presentation at the 35th Annual J.P. Morgan Healthcare Conference 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dova Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dova Pharma Raises USD10 Million in Venture Financing 10
Dova Pharma and Valeant Pharma Enter into Co-Promotion Agreement 11
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 12
Dova Pharma Plans to Raise up to USD300 Million in Public Offering of Securities 13
Dova Pharma Prices Public Offering of Shares for USD80 Million 14
Dova Pharma Raises USD75 Million in IPO 15
Dova Pharma Raises USD0.2 Million in Private Placement of Units 16
Perceptive Advisor Acquires 6.8% Stake in Dova Pharma 17
Dova Pharma Acquires AkaRx from Eisai 18
Dova Pharmaceuticals Inc, Key Competitors 19
Dova Pharmaceuticals Inc, Key Employees 20
Dova Pharmaceuticals Inc, Subsidiaries 21

List of Figures
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Dova Pharmaceuticals Inc (DOVA):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8176)販売に関する免責事項を必ずご確認ください。
★調査レポート[Dova Pharmaceuticals Inc (DOVA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆